A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Blood

Volumn 123, Issue 13, 2014, Pages 2026-2033

  Tong, Wing H ^a   Pieters, Rob ^a,b   Kaspers, Gertjan J L ^c   Te Loo, D Maroeska W M ^d   Bierings, Marc B ^e   Van Den Bos, Cor ^f   Kollen, Wouter J W ^g   Hop, Wim C J ^h   Lanvers Kaminsky, Claudia ⁱ   Relling, Mary V ^j   Tissing, Wim J E ^k   Van Der Sluis, Inge M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DCOG Dutch Childhood Oncology Group   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE ANTIBODY; ASPARAGINASE MACROGOL; ASPARAGINE; CLEMASTINE; ENZYME ANTIBODY; HYDROCORTISONE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD CHEMISTRY; CANCER PATIENT; CHILD; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INACTIVATION; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PEDIATRICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADOLESCENT; ANTIBODIES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; ERWINIA; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; INFANT; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897507642     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-534347     Document Type: Article

References (35)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
2. Bussolati O, Belletti S, Uggeri J, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res. 1995;220(2):283-291.
3. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101(7):2743-2747. (Pubitemid 36857638)
4. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-342. (Pubitemid 29108071)
5. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218. (Pubitemid 32183741)
6. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-2739. (Pubitemid 34525359)
7. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896-904. (Pubitemid 46220632)
8. Panosyan EH, Seibel NL, Martin-Aragon S, et al; Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-226. (Pubitemid 38500969)
9. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238-249.
10. Willer A, Gerss J, König T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118(22):5774-5782.
11. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Młynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9(2):113-116.
12. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202-1210.
13. Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia. 2003;17(8):1583-1588. (Pubitemid 36992159)
14. Wenner KA, Vieira Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005;217(6):321-326. (Pubitemid 41746113)
15. Albertsen BK, Schrøder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol. 2001;115(4):983-990. (Pubitemid 34042920)
16. Albertsen BK, Schrøder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol. 2002;38(5):310-316. (Pubitemid 34493110)
17. Tong WH, van der Sluis IM, Alleman CJ, et al. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica. 2013;98(5):753-759.
18. Lenda K, Svenneby G. Rapid high-performance liquid chromatographic determination of amino acids in synaptosomal extracts. J Chromatogr A. 1980;198(4):516-519. (Pubitemid 11218986)
19. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32(9):1544-1550. (Pubitemid 26279122)
20. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119(7):1658-1664.
21. Tong WH, Pieters R, Hop WC, Lanvers-Kaminsky C, Boos J, van der Sluis IM. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer. 2013;60(2):258-261.
22. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24-31. (Pubitemid 43235382)
23. 2 achieves adequate trough activity levels in the majority of patients treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) protocol [abstract]. Blood. 2011;118(21). Abstract 2573.
24. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665-1679.
25. Müller HJ, Löning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110(2):379-384. (Pubitemid 30646864)
26. Vrooman LM, Kirov II, Dreyer ZE, et al. Preliminary results of a pharmacokinetic study of intravenous asparaginase Erwinia chrysanthemi following allergy to E. coli-derived asparaginase in children, adolescents, and young adults with acute lymphoblastic leukemia or lymphoblastic lymphoma [abstract]. Blood. 2013;122(21). Abstract 3904.
27. Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507-514.
28. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol. 2000;11(2):189-193. (Pubitemid 30148733)
29. Albertsen BK, Schrøder H, Jakobsen P, Müller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001;52(4):433-437. (Pubitemid 32939446)
30. Gentili D, Conter V, Rizzari C, et al. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol. 1996;7(7):725-730. (Pubitemid 26323546)
31. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991-998. (Pubitemid 47359142)
32. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629. (Pubitemid 129735360)
33. Lanvers-Kaminsky C, Schulze-Westhoff P, D'Incalci M, Zucchetti M, Boos J. Immediate cooling does not prevent the ex-vivo hydrolysis of L-asparagine by asparaginase [published online ahead of print December 13, 2013]. Ther Drug Monit.
34. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61(3):208-221. (Pubitemid 46329425)
35. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1(3):241-254.